Dr. Sulaiman Faqih Hospital – Jeddah has achieved a new medical milestone by performing the first autologous stem cell transplant in the private sector in the Kingdom of Saudi Arabia, for a 55-year-old patient suffering from multiple myeloma, in a step that reflects the development of specialized services in the treatment of blood diseases and tumors, and enhances the hospital’s position as a leading center for advanced healthcare.

The hospital’s stem cell transplant and cell therapy program witnessed the launch of its first operation by performing an autologous stem cell transplant on the patient, and the operation was successful, confirming the program’s readiness to provide this type of precise treatment in accordance with the latest international medical standards and protocols.

Dr. Mazen Faqih, Chairman of Faqih Healthcare Group, affirmed: “This achievement represents a qualitative step in the group’s journey towards providing the latest specialized medical services, and reflects its ongoing commitment to providing advanced healthcare in accordance with the best global practices, which contributes to enhancing the quality of healthcare within the Kingdom.”

Autologous stem cell transplantation is a cornerstone of treatment for medically eligible patients with multiple myeloma. This procedure involves collecting stem cells from the patient after initial treatment, administering high doses of chemotherapy to eliminate as many cancer cells as possible, and then reinjecting the stem cells to rebuild the bone marrow and accelerate the recovery of blood cell production. This technique contributes to a deeper response to treatment, longer disease control, and improved treatment outcomes and quality of life for patients.

For his part, Dr. Ahmed Al-Saeed, Consultant Hematologist and Bone Marrow Transplant Specialist at Dr. Sulaiman Faqih Hospital - Jeddah, explained that the success of the first autologous stem cell transplant within the stem cell transplant and cell therapy program reflects the hospital’s readiness in terms of medical expertise and specialized equipment, and allows patients to obtain this type of advanced treatment within the Kingdom according to the highest international standards.

It is worth noting that the Oncology Center at Dr. Sulaiman Faqih Hospital in Jeddah is considered one of the leading centers in providing comprehensive and integrated care for cancer patients, from early diagnosis through treatment to follow-up. The center includes a multidisciplinary team of consultants in surgical oncology, medical oncology, radiation therapy, and histopathology, along with specialized nursing staff and services for psychological support and therapeutic nutrition. The team operates within a cancer board model, where each case is discussed to develop the most appropriate treatment plan.

The center offers a wide range of advanced services including complex and delicate tumor surgeries, endoscopic and robotic tumor surgeries, chemotherapy, immunotherapy, targeted therapy, and radiation therapy with the latest technologies, in addition to early detection programs and comprehensive examinations, and psychological and rehabilitative support services for cancer patients and their families.

This achievement confirms the advanced position of Dr. Sulaiman Faqih Hospital - Jeddah in providing specialized care for cancer and blood disease patients, and reflects the readiness of its infrastructure and medical competencies to provide advanced treatments according to best global practices, which enhances the quality of health care provided to patients.

-I finish-

#Company Data

Disclaimer regarding the content of press releases
The content of this press release is provided by a third-party provider. We do not assume any responsibility for, nor do we have any control over, such content. This content is provided on an "as is" and "as available" basis and is not edited in any way. Neither we, nor our affiliates, will be liable for the accuracy, endorsement, or completeness of any opinions, views, information, or materials contained in this content.
This press release is provided for informational purposes only; the content does not constitute legal, investment, or tax advice, nor does it offer any opinion on the suitability, value, or profitability of any particular portfolio or investment strategy. Neither we nor our affiliates will be liable for any errors or inaccuracies in the content, or for any actions you take based on that content. You expressly agree and acknowledge full responsibility for your use of the information contained in this press release.
To the extent permitted by applicable law, Refinitiv, its parent company, subsidiaries, affiliates, relevant shareholders, directors, officers, employees, agents, advertisers, content providers, and licensors (collectively, the 'Refinitiv Parties') shall not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive, or exemplary damages; This includes, but is not limited to, losses of profits, savings, or revenues, whether due to negligence, tort, contract, or other theories of liability, even if the parties to Refinitiv were advised of the possibility of any such damages or losses occurring or actually anticipated them.